PuSH - Publikationsserver des Helmholtz Zentrums München

Schork, A. ; Artunc, F.

Behandlungsstrategien bei diabetischer Nephropathie – Update 2022.

Treatment strategies in diabetic nephropathy - Update 2022.

Dtsch. Med. Wochenschr. 147, 1476-1481 (2022)
Postprint DOI PMC
Open Access Green
TREATMENT GOALS IN DIABETIC NEPHROPATHY:  A new classification of patients with diabetes mellitus into so-called clusters can be used to assess the risk of developing diabetic nephropathy. Up to date treatment of patients with diabetic nephropathy includes not only glycemic control, but focuses on a holistic approach with prevention of (progression of) secondary diabetic complications and reduction of the patient's cardiovascular mortality. COMPONENTS OF TREATMENT OF DIABETIC NEPHROPATHY:  To achieve this treatment goals, it requires comprehensive management of the patient to implement lifestyle interventions (regarding diet, physical activity, weight loss, smoking cessation) and selection of the medication with the greatest individual benefit. DIETARY RECOMMENDATIONS IN DIABETIC NEPHROPATHY:  Part of lifestyle intervention is adherence to a dietary regimen that has again been shown in recent studies to be relevant in inhibiting progression of chronic kidney disease and reducing cardiovascular risk. In particular, this includes protein restriction with preference for plant sources of protein, and salt restriction. USE OF MEDICATION CLASSES WITH PROVEN CARDIORENAL BENEFITS:  Adjustment of drug therapy is no longer based on antihyperglycemic effects alone, but takes into account inhibition of progression of nephropathy and cardiac risk, as well as support of body weight control. For this purpose, in addition to RAAS inhibitors from the field of antihypertensives, the antidiabetic classes of SGLT2 inhibitors and GLP-1 receptor agonists as well as the non-steroidal aldosterone antagonist finerenone are now available.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Korrespondenzautor
ISSN (print) / ISBN 0012-0472
e-ISSN 1439-4413
Zeitschrift Deutsche Medizinische Wochenschrift - DMW
Quellenangaben Band: 147, Heft: 22, Seiten: 1476-1481 Artikelnummer: , Supplement: ,
Verlag Thieme
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Diabetes Research and Metabolic Diseases (IDM)